11:49 AM EDT, 04/15/2024 (MT Newswires) -- Marinus Pharmaceuticals ( MRNS ) shares fell past 79% in recent Monday trading after the company said that a phase 3 trial of ganaxolone did not meet pre-defined stopping criteria at the interim analysis.

The study was designed to evaluate intravenous ganaxolone for the treatment of refractory status epilepticus, the company said.

An independent data monitoring committee has recommended continuing the trial, the company said, adding that it has decided to complete enrollment at about 100 patients.

Topline results, which are expected in the summer of 2024, will determine whether to continue the development of IV ganaxolone, the company said.

Marinus added that it remains blinded to the trial data.